Artiva Biotherapeutics, Inc. (ARTV) Stock Price & Analysis
Artiva Biotherapeutics, Inc. (ARTV) fell 0.99% to USD 10.03 as of July 25, 2026 at 03:41 UTC, according to Nexqual real-time market data.
ARTV last closed at USD 10.13; the session ranged USD 9.74–11.3 on volume of 559,410 shares. Market capitalization is $487.34M, with a 52-week range of USD 2.22–14.53 (NGM). Source: Nexqual, July 25, 2026 at 03:41 UTC.
Key Statistics (as of July 25, 2026 at 03:41 UTC)
| Price | USD 10.03 |
|---|---|
| Change | ▼ 0.99% (down) |
| Previous Close | USD 10.13 |
| Open | USD 10.52 |
| Day Range | USD 9.74 – 11.3 |
| 52-Week Range | USD 2.22 – 14.53 |
| Volume | 559,410 shares |
| Market Cap | $487.34M |
| Exchange | NGM |
Technical Analysis (ARTV)
Nexqual's technical model rates ARTV "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 03:41 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 60.17 (neutral) |
| vs SMA50 | Above (USD 8.88) |
| MACD | 0.26 (positive) |
Analyst Ratings (ARTV)
Wall Street analysts rate ARTV "None" based on 5 analysts, with a mean price target of USD 35.8 (range USD 23–41), per Nexqual as of July 25, 2026 at 03:41 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 35.8 |
| High Target | USD 41 |
| Low Target | USD 23 |
| Buy / Hold / Sell | 6 / 0 / 0 |
Earnings (ARTV)
| EPS Estimate | USD -0.64 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.95 vs est -0.84 ▼ miss |
| 2025-12-31 | USD -0.84 vs est -0.8 ▼ miss |
| 2025-09-30 | USD -0.88 vs est -0.8 ▼ miss |
| 2025-06-30 | USD -0.87 vs est -0.77 ▼ miss |
Source: Nexqual, July 25, 2026 at 03:41 UTC.
Financials & Fundamentals (ARTV)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -67.86% |
| Debt / Equity | 11.68 |
| Current Ratio | 8.16 |
| Total Cash | $86.78M |
| Total Debt | $10.26M |
| Free Cash Flow | $-49.42M |
Source: Nexqual, July 25, 2026 at 03:41 UTC.
Financial Health Score (ARTV)
Nexqual rates Artiva Biotherapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 03:41 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $87M cash vs $10M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$78M |
| Efficiency | Critical — ROE -68%, ROA -38.7% |
Ownership (ARTV)
| Insider Ownership | +14.14% |
|---|---|
| Institutional Ownership | +52.02% |
| Shares Outstanding | 48.59M |
| Float | 10.01M |
| Short % of Float | +3.94% |
Source: Nexqual, July 25, 2026 at 03:41 UTC.
Leadership (ARTV)
Artiva Biotherapeutics, Inc. is led by Fred Aslan (age 50), CEO, Principal Financial & Accounting Officer and Director, per Nexqual as of July 25, 2026 at 03:41 UTC.
| CEO, Principal Financial & Accounting Officer and Director | Fred Aslan (age 50) |
|---|---|
| President and Head of Research & Development | Gines Diego Miralles (age 62) |
| Chief Operating Officer | Jennifer Kinsbruner Bush Esq. (age 50) |
| Vice President of Corporate Development | Nicholas Veomett |
| Senior Vice President of Research & Early Development | Heather Raymon (age 60) |
Major Backers & Investors (ARTV)
Notable institutional backers of Artiva Biotherapeutics, Inc. include RA Capital Management, L.P., 5AM Venture Management, LLC, Venrock Adviser, LLC, according to Nexqual as of July 25, 2026 at 03:41 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 39.87% |
| 5AM Venture Management, LLC | 9.52% |
| Venrock Adviser, LLC | 6.51% |
| venBio Partners LLC | 2.15% |
| Franklin Resources, Inc. | 2.11% |
| Revelation Capital Management, LLC | 1.21% |
| Wellington Management | 0.79% |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 0.78% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 1.68% |
| BlackRock | 0.9% |
Source: Nexqual, July 25, 2026 at 03:41 UTC.
From Artiva Biotherapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-03-10)
Key Strengths & Strategy (as disclosed to the SEC)
- Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers.
- Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
- The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ALMS | Alumis Inc. | USD 28 | ▼ 2.81% |
| KYTX | Kyverna Therapeutics, Inc. | USD 7.41 | ▲ 0.14% |
| ANRO | Alto Neuroscience, Inc. | USD 26.78 | ▼ 1.65% |
| QTTB | Q32 Bio Inc. | USD 15.15 | ▲ 0.46% |
| MBX | MBX Biosciences, Inc. | USD 62 | ▲ 6.35% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:41 UTC. This page is informational and not investment advice.